Skip to main content
. Author manuscript; available in PMC: 2016 Jan 31.
Published in final edited form as: Leuk Res. 2014 Nov 29;39(2):229–235. doi: 10.1016/j.leukres.2014.11.006

Figure 3. F10 treatment induces activation of NF-κB promotes survival in HL-60 cells.

Figure 3

(A) Western blot for NF-kB p65 sub-unit evaluating cytoplasmic/nuclear ((C)/(N)) expression under the treatment conditions as indicated. (B) Western blot for c-Jun and p-c-Jun in control and F10-treated HL-60 cells at the indicated times. c-Jun is activated at 24 and 48 h consistent with AP-1 activation in response to F10 treatment. (C) F10-induced activation of caspase 3/7 activity is significantly enhanced at 48 h by NF-κB inhibition. (D) Western blot showing no change in expression for either Fas or FasL in HL-60 cells treated with F10 for 24, 48, or 72 h.